Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMDW 57 EV-to-EBIT is 0.00 as of Sep. 09, 2026. GuruFocus rates BTMDW with a GF Score™ of 57/100. The stock has 2 warning signs investors should review. Among 476 Healthcare Providers & Services companies, Biote ranks better than 78.78% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biote's Enterprise Value is $0.00 Mil.
Biote's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $19.62 Mil. Therefore, Biote's EV-to-EBIT for today is 0.00.
The historical rank and industry rank for Biote's EV-to-EBIT or its related term are showing as below:
BTMDW'
s EV-to-EBIT Range Over the Past 10 Years
Min: -12.25 Med: 5.86 Max: 40.73
Current: 8.58
During the past 7 years, the highest EV-to-EBIT of Biote was 40.73. The lowest was -12.25. And the median was 5.86.
BTMDW's EV-to-EBIT is ranked better than 78.78% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 15.155
vs BTMDW: 8.58
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biote's Enterprise Value for the quarter that ended in Jun. 2026 was $0.00 Mil.
Biote's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote EV-to-EBIT Related Terms
Biote EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Biote's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Biote's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Biote's EV-to-EBIT falls into.
Biote's current Enterprise Value is $0.00 Mil.
Biote's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMDW) has a EV-to-EBIT of 0.00 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biote and its competitors. According to the industry distribution chart, Biote ranks #101 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 21.2%.
Is Biote's EV-to-EBIT too high?
Biote's current EV-to-EBIT is 0.00. Based on the distribution chart, Biote ranks #101 out of 476 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Biote has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Biote's EV-to-EBIT compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #101 out of 476 companies for EV-to-EBIT. This places Biote in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.16, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Biote (BTMDW) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Biote's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biote (BTMDW), the current EV-to-EBIT is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
57GF Score
Get the complete analysis for BTMDW
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMDW has been successfully added to your 
